Cover
Cover - shares | 6 Months Ended | |
Jun. 30, 2020 | Jul. 30, 2020 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2020 | |
Document Transition Report | false | |
Entity File Number | 001-33462 | |
Entity Registrant Name | INSULET CORPORATION | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 04-3523891 | |
Entity Address, Address Line One | 100 Nagog Park | |
Entity Address, City or Town | Acton | |
Entity Address, State or Province | MA | |
Entity Address, Postal Zip Code | 01720 | |
City Area Code | 978 | |
Local Phone Number | 600-7000 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Title of 12(b) Security | Common Stock, $0.001 Par Value Per Share | |
Trading Symbol | PODD | |
Security Exchange Name | NASDAQ | |
Entity Common Stock, Shares Outstanding (in shares) | 65,650,528 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q2 | |
Entity Central Index Key | 0001145197 | |
Current Fiscal Year End Date | --12-31 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Current Assets | ||
Cash and cash equivalents | $ 779.1 | $ 213.7 |
Short-term investments | 65.3 | 162.4 |
Accounts receivable trade, less allowance for credit losses of $4.6 and $3.8 | 78 | 69.3 |
Inventories | 103.7 | 101 |
Prepaid expenses and other current assets | 59.6 | 44.6 |
Total current assets | 1,085.7 | 591 |
Long-term investments | 23.5 | 58.4 |
Property, plant and equipment, net | 423.2 | 399.4 |
Other intangible assets, net | 10.9 | 13.2 |
Goodwill | 39.6 | 39.8 |
Other assets | 43.8 | 41.1 |
Total assets | 1,626.7 | 1,142.9 |
Current Liabilities | ||
Accounts payable | 35.6 | 54.5 |
Accrued expenses and other current liabilities | 98.8 | 103.2 |
Total current liabilities | 134.4 | 157.7 |
Convertible debt, net | 910.2 | 887.9 |
Other liabilities | 18.8 | 21.4 |
Total liabilities | 1,063.4 | 1,067 |
Commitments and contingencies (Note 9) | ||
Stockholders’ Equity | ||
Preferred stock, $.001 par value, 5,000,000 authorized; none issued and outstanding | 0 | 0 |
Common stock, $.001 par value, 100,000,000 authorized; 65,604,347 and 62,685,492 issued and outstanding | 0.1 | 0.1 |
Additional paid-in capital | 1,227.6 | 749 |
Accumulated deficit | (660.8) | (672) |
Accumulated other comprehensive loss | (3.6) | (1.2) |
Total stockholders’ equity | 563.3 | 75.9 |
Total liabilities and stockholders’ equity | $ 1,626.7 | $ 1,142.9 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts | $ 4.6 | $ 3.8 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, issued (in shares) | 0 | 0 |
Preferred stock, outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, issued (in shares) | 65,604,347 | 62,685,492 |
Common stock, outstanding (in shares) | 65,604,347 | 62,685,492 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Income Statement [Abstract] | ||||
Revenue | $ 226.3 | $ 177.1 | $ 424.3 | $ 336.7 |
Cost of revenue | 83.8 | 60.7 | 154.9 | 113.6 |
Gross profit | 142.5 | 116.4 | 269.4 | 223.1 |
Operating expenses: | ||||
Research and development expenses | 34.2 | 33 | 69.7 | 65.5 |
Selling, general and administrative expenses | 80.8 | 75.8 | 164.7 | 142.7 |
Operating income | 27.5 | 7.6 | 35 | 14.9 |
Interest expense, net | (11.1) | (5.8) | (21.2) | (10.6) |
Other income, net | 1 | 0.1 | 1 | 2.3 |
Income before income taxes | 17.4 | 1.9 | 14.8 | 6.6 |
Income tax expense | (3) | (0.5) | (2.5) | (0.8) |
Net income | $ 14.4 | $ 1.4 | $ 12.3 | $ 5.8 |
Net income per share: | ||||
Basic (in dollars per share) | $ 0.22 | $ 0.02 | $ 0.19 | $ 0.10 |
Diluted (in dollars per share) | $ 0.22 | $ 0.02 | $ 0.19 | $ 0.09 |
Weighted-average number of common shares outstanding: | ||||
Basic (in shares) | 64,370,791 | 59,844,991 | 63,627,231 | 59,601,365 |
Diluted (in shares) | 65,578,513 | 61,486,325 | 64,970,187 | 61,332,451 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 14.4 | $ 1.4 | $ 12.3 | $ 5.8 |
Other comprehensive income (loss), net of tax: | ||||
Currency translation adjustment | 0.6 | (0.4) | (2.8) | (1.2) |
Unrealized (loss) gain on available-for-sale debt securities | (0.4) | 0.7 | 0.4 | 1.3 |
Total other comprehensive income (loss), net of tax | 0.2 | 0.3 | (2.4) | 0.1 |
Comprehensive income | $ 14.6 | $ 1.7 | $ 9.9 | $ 5.9 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions | Total | Cumulative Effect, Period of Adoption, Adjustment | Common Stock | Common StockCumulative Effect, Period of Adoption, Adjustment | Additional Paid-in Capital | Accumulated Deficit | Accumulated DeficitCumulative Effect, Period of Adoption, Adjustment | Accumulated Other Comprehensive Loss |
Beginning balance (in shares) at Dec. 31, 2018 | 59,188,758 | |||||||
Beginning balance at Dec. 31, 2018 | $ 212.1 | $ 0.1 | $ 898.5 | $ (683.6) | $ (2.9) | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Exercise of options to purchase common stock (in shares) | 716,687 | |||||||
Exercise of options to purchase common stock | 23.6 | 23.6 | ||||||
Issuance of employee stock purchase plan (in shares) | 27,613 | |||||||
Issuance of employee stock purchase plan | 2 | 2 | ||||||
Stock-based compensation | 14.1 | 14.1 | ||||||
Restricted stock units vested, net of shares withheld for taxes (in shares) | 216,868 | |||||||
Restricted stock units vested, net of shares withheld for taxes | (7.9) | (7.9) | ||||||
Net income | 5.8 | 5.8 | ||||||
Other comprehensive income | 0.1 | 0.1 | ||||||
Ending balance (in shares) at Jun. 30, 2019 | 60,149,926 | |||||||
Ending balance at Jun. 30, 2019 | 249.8 | $ 0.1 | 930.3 | (677.8) | (2.8) | |||
Beginning balance (in shares) at Dec. 31, 2018 | 59,188,758 | |||||||
Beginning balance at Dec. 31, 2018 | $ 212.1 | $ 0.1 | 898.5 | (683.6) | (2.9) | |||
Ending balance (in shares) at Dec. 31, 2019 | 62,685,492 | 62,685,492 | 0 | |||||
Ending balance at Dec. 31, 2019 | $ 75.9 | $ (1.1) | $ 0.1 | 749 | (672) | $ (1.1) | (1.2) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Accounting Standards Update [Extensible List] | us-gaap:AccountingStandardsUpdate201613Member | |||||||
Beginning balance (in shares) at Mar. 31, 2019 | 59,638,439 | |||||||
Beginning balance at Mar. 31, 2019 | $ 223.6 | $ 0.1 | 905.8 | (679.2) | (3.1) | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Exercise of options to purchase common stock (in shares) | 447,214 | |||||||
Exercise of options to purchase common stock | 14.6 | 14.6 | ||||||
Issuance of employee stock purchase plan (in shares) | 27,613 | |||||||
Issuance of employee stock purchase plan | 2 | 2 | ||||||
Stock-based compensation | 8.3 | 8.3 | ||||||
Restricted stock units vested, net of shares withheld for taxes (in shares) | 36,660 | |||||||
Restricted stock units vested, net of shares withheld for taxes | (0.4) | (0.4) | ||||||
Net income | 1.4 | 1.4 | ||||||
Other comprehensive income | 0.3 | 0.3 | ||||||
Ending balance (in shares) at Jun. 30, 2019 | 60,149,926 | |||||||
Ending balance at Jun. 30, 2019 | $ 249.8 | $ 0.1 | 930.3 | (677.8) | (2.8) | |||
Beginning balance (in shares) at Dec. 31, 2019 | 62,685,492 | 62,685,492 | 0 | |||||
Beginning balance at Dec. 31, 2019 | $ 75.9 | $ (1.1) | $ 0.1 | 749 | (672) | $ (1.1) | (1.2) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Issuance of common stock (in shares) | 2,369,668 | |||||||
Issuance of common stock | 477.5 | 477.5 | ||||||
Exercise of options to purchase common stock (in shares) | 304,374 | |||||||
Exercise of options to purchase common stock | 11.3 | 11.3 | ||||||
Issuance of employee stock purchase plan (in shares) | 18,685 | |||||||
Issuance of employee stock purchase plan | 2.9 | 2.9 | ||||||
Stock-based compensation | 13.7 | 13.7 | ||||||
Restricted stock units vested, net of shares withheld for taxes (in shares) | 226,128 | |||||||
Restricted stock units vested, net of shares withheld for taxes | (26.8) | (26.8) | ||||||
Net income | 12.3 | 12.3 | ||||||
Other comprehensive income | $ (2.4) | (2.4) | ||||||
Ending balance (in shares) at Jun. 30, 2020 | 65,604,347 | 65,604,347 | ||||||
Ending balance at Jun. 30, 2020 | $ 563.3 | $ 0.1 | 1,227.6 | (660.8) | (3.6) | |||
Beginning balance (in shares) at Mar. 31, 2020 | 63,057,874 | |||||||
Beginning balance at Mar. 31, 2020 | 59 | $ 0.1 | 737.9 | (675.2) | (3.8) | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Issuance of common stock (in shares) | 2,369,668 | |||||||
Issuance of common stock | 477.5 | 477.5 | ||||||
Exercise of options to purchase common stock (in shares) | 131,542 | |||||||
Exercise of options to purchase common stock | 5.1 | 5.1 | ||||||
Issuance of employee stock purchase plan (in shares) | 18,685 | |||||||
Issuance of employee stock purchase plan | 2.9 | 2.9 | ||||||
Stock-based compensation | 5.8 | 5.8 | ||||||
Restricted stock units vested, net of shares withheld for taxes (in shares) | 26,578 | |||||||
Restricted stock units vested, net of shares withheld for taxes | (1.6) | (1.6) | ||||||
Net income | 14.4 | 14.4 | ||||||
Other comprehensive income | $ 0.2 | 0.2 | ||||||
Ending balance (in shares) at Jun. 30, 2020 | 65,604,347 | 65,604,347 | ||||||
Ending balance at Jun. 30, 2020 | $ 563.3 | $ 0.1 | $ 1,227.6 | $ (660.8) | $ (3.6) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Cash flows from operating activities | ||
Net income | $ 12.3 | $ 5.8 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 18.8 | 11 |
Non-cash interest | 22.3 | 15.4 |
Stock-based compensation | 13.7 | 14.1 |
Provision for credit losses | 2.6 | 2 |
Other | 0 | (0.6) |
Changes in operating assets and liabilities: | ||
Accounts receivable | (13.8) | (7) |
Inventories | (2.8) | (14) |
Prepaid expenses and other assets | (14) | (1.5) |
Accounts payable, accrued expenses and other current liabilities | (13.9) | (3.5) |
Other liabilities | (2.4) | (1.3) |
Net cash provided by operating activities | 22.8 | 20.4 |
Cash flows from investing activities | ||
Capital expenditures | (51.7) | (91.9) |
Acquisition of intangible assets | (0.5) | (5) |
Purchases of investments | (37.9) | (39.1) |
Receipts from the maturity or sale of investments | 170.7 | 104.2 |
Net cash provided by (used in) investing activities | 80.6 | (31.8) |
Cash flows from financing activities | ||
Proceeds from issuance of common stock, net of issuance costs | 477.5 | 0 |
Proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan | 14.2 | 25.6 |
Payment of withholding taxes in connection with vesting of restricted stock units | (26.8) | (7.9) |
Net cash provided by financing activities | 464.9 | 17.7 |
Effect of exchange rate changes on cash | (2.9) | (0.3) |
Net increase in cash, cash equivalents and restricted cash | 565.4 | 6 |
Cash, cash equivalents and restricted cash at beginning of period | 213.7 | 113.9 |
Cash, cash equivalents and restricted cash at end of period | 779.1 | 119.9 |
Supplemental cash flow information: | ||
Purchases of property and equipment included in accounts payable and accrued expenses | $ 4.5 | $ 3 |
Basis of Presentation and Summa
Basis of Presentation and Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Summary of Significant Accounting Policies | Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements reflect the consolidated operations of Insulet Corporation and its subsidiaries (“Insulet” or the “Company”). The unaudited consolidated financial statements have been prepared in United States dollars, in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the consolidated financial statements in conformity with GAAP requires management to make use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. Actual results may differ from those estimates. In management’s opinion, the unaudited consolidated financial statements contain all normal recurring adjustments necessary for a fair statement of the interim results reported. Operating results for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2020, or for any other subsequent interim period. The year-end balance sheet data was derived from audited consolidated financial statements. These unaudited consolidated financial statements do not include all of the annual disclosures required by GAAP; accordingly, they should be read in conjunction with the Company’s audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Accounts Receivable and Allowance for Credit Losses Trade accounts receivable consist of amounts due from third-party payors, customers and intermediaries and are presented at amortized cost. The allowance for credit losses reflects an estimate of losses inherent in the Company’s accounts receivable portfolio determined based on historical experience, specific allowances for known troubled accounts and other available evidence. Accounts receivable are written off when management determines they are uncollectable. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist. The Company has identified the following portfolio segments and measures the allowance for credit losses using the following methods: Direct Customer Receivables —The Company measures expected credit losses on direct customer receivables using an aging methodology. The risk of loss for direct customer receivables is higher than other portfolios. The Company relies on third-party payors to accept and timely process claims and on direct consumers to have the ability to pay. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and supportable forecasts. Distributor Receivables —The Company measures expected credit losses on distributor receivables using an individual reserve methodology. The risk of loss in this portfolio is low based on the Company’s historical experience. The estimate of expected credit losses considers payment history as well as credit ratings of the distributors, in addition to current conditions and supportable forecasts. National Healthcare System Receivables —The Company measures expected credit losses on national healthcare system receivables using an individual reserve methodology. The risk of loss in this portfolio is low based on the Company’s historical experience. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and supportable forecasts. Shipping and Handling Costs Shipping and handling costs are included in selling, general and administrative expenses and were $1.9 million and $2.3 million for the three months ended June 30, 2020 and 2019, respectively, and were $3.8 million and $4.9 million for the six months ended June 30, 2020 and 2019, respectively. Fair Value Measurements Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. To measure fair value of assets and liabilities, the Company uses the following fair value hierarchy based on three levels of inputs: Level 1—observable inputs, such as quoted prices in active markets for identical assets or liabilities; Level 2—significant other observable inputs that are observable either directly or indirectly; and Level 3—significant unobservable inputs for which there are little or no market data, which require the Company to develop its own assumptions. Certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities are carried at cost, which approximates their fair value because of their short-term maturity. See Notes 3 and 8 for financial assets and liabilities held at carrying amount on the consolidated balance sheet and Note 4 for investments measured at fair value on a recurring basis. Reclassification of Prior Period Amounts Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation. A portion of facility costs and certain information technology costs have been allocated from selling, general and administrative to research and development expenses based on square foot and system usage, respectively. In addition, certain quality assurance costs were reclassified from research and development expenses to selling, general and administrative expenses. The net impact of these adjustments wa s a $0.7 million and $1.3 million increase to research and development expenses and a corresponding decrease to selling, general and administrative expenses for the three and six months ended June 30, 2020, respectively . There was no change to previously reported operating or net income. Further, the Company reclassified the $1.6 million chang e in unbilled receivables from the change in accounts and unbilled receivables to the change in prepaid expenses and other assets in the prior year statement of cash flows. This reclassification had no effect on previously reported net cash provided by operating activities. Recently Adopted Accounting Standards Effective January 1, 2020, the Company adopted Accounting Standards Update (“ASU”) 2016-13, Credit Losses (Topic 326) (“ASU 2016-13”). ASU 2016-13 requires financial assets measured at amortized cost, such as the Company’s trade receivables and contract assets, to be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions and future expectation for each pool of similar financial assets. The new guidance also requires enhanced disclosures related to trade receivables and associated credit losses. The Company adopted ASU 2016-13 using the modified retrospective method, whereby the guidance is applied prospectively as of the date of adoption and prior periods are not restated. The cumulative effect of adopting ASU 2016-13 The following table presents the activity in the allowance for credit losses for the three and six months ended June 30, 2020 , comprised primarily of our direct consumer receivable portfolio. The allowance for credit losses of other portfolios is insignificant. (in millions) Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Credit losses at the beginning of the period $ 4.1 $ 3.8 Effect of adoption — 1.1 Credit losses at the beginning of the period after adoption 4.1 4.9 Provision for expected credit losses 2.0 2.6 Write-offs charged against allowance (1.6) (3.1) Recoveries of amounts previously written-off 0.1 0.2 Credit losses at the end of the period $ 4.6 $ 4.6 Effective January 1, 2020, the Company adopted ASU 2017-04, Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). ASU 2017-04 requires an entity to measure the impairment of goodwill assigned to a reporting unit as the amount by which the carrying value of the assets and liabilities of the reporting unit, including goodwill, exceeds the reporting units’ fair value. The adoption of this guidance had no impact on the consolidated financial statements. |
Revenue and Contract Acquisitio
Revenue and Contract Acquisition Costs | 6 Months Ended |
Jun. 30, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Revenue and Contract Acquisition Costs | Revenue and Contract Acquisition Costs The following table summarizes the Company’s disaggregated revenues: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 U.S. Omnipod $ 128.8 $ 98.1 $ 245.4 $ 184.2 International Omnipod 73.2 62.7 146.3 119.6 Total Omnipod 202.0 160.8 391.7 303.8 Drug Delivery 24.3 16.3 32.6 32.9 Total $ 226.3 $ 177.1 $ 424.3 $ 336.7 During both the three and six months ended June 30, 2020, the Company had two customers that represented 21% of total revenue. During the three and six months ended June 30, 2019, the Company had one customer that represented 12% of total revenue and two customers that represented 21% of total revenue, respectively. Deferred revenue related to unsatisfied performance obligations was included in the following consolidated balance sheet accounts in the amounts shown: (in millions) June 30, 2020 December 31, 2019 Accrued expenses and other current liabilities $ 5.0 $ 3.2 Other liabilities 0.9 1.0 Total deferred revenue $ 5.9 $ 4.2 Revenue recognized during the three and six months ended June 30, 2020 included in deferred revenue at the beginning of 2020 was $0.1 million and $1.6 million, respectively. Revenue recognized during the three and six months ended June 30, 2019 included in deferred revenue at the beginning of 2019 was $0.2 million and $1.1 million, respectively. Contract acquisition costs, representing capitalized commission costs related to new customers, net of amortization, were included in the following consolidated balance sheet captions in the amounts shown: (in millions) June 30, 2020 December 31, 2019 Prepaid expenses and other current assets $ 9.9 $ 9.5 Other assets 19.7 19.9 Total capitalized contract acquisition costs, net $ 29.6 $ 29.4 The Company had unbilled receivables of $22.3 million and $13.5 million at June 30, 2020 and December 31, 2019, respectively. The Company recognized $2.6 million and $5.1 million of amortization of capitalized contract acquisition costs during the three and six months ended June 30, 2020, respectively. The Company recognized $2.1 million and $4.1 million of amortization of capitalized contract acquisition costs during the three and six months ended June 30, 2019, respectively. |
Cash and Cash Equivalents
Cash and Cash Equivalents | 6 Months Ended |
Jun. 30, 2020 | |
Cash and Cash Equivalents [Abstract] | |
Cash and Cash Equivalents | Cash and Cash Equivalents The following table provides a summary of cash and cash equivalents and the level in the fair value hierarchy in which those measurements fall: June 30, 2020 December 31, 2019 (in millions) Total Level 1 Level 2 Total Level 1 Level 2 (1) Cash $ 470.3 $ 470.3 $ — $ 85.3 $ 85.3 $ — Money market mutual funds 305.9 305.9 — 115.5 115.5 — Commercial paper — — — 10.0 — 10.0 Restricted cash 2.9 2.9 — 2.9 2.9 — Total cash and cash equivalents $ 779.1 $ 779.1 $ — $ 213.7 $ 203.7 $ 10.0 (1) Fair value was determined using market prices obtained from third-party pricing sources. |
Investments
Investments | 6 Months Ended |
Jun. 30, 2020 | |
Investments, Debt and Equity Securities [Abstract] | |
Investments | Investments The Company’s short-term and long-term investments in debt securities had maturity dates that range from one month to two years at June 30, 2020 . Realized gains or losses for both the three and six months ended June 30, 2020 and 2019 were insignificant. The following table provides amortized costs, gross unrealized gains and losses, fair values and the level in the fair value hierarchy for the Company’s investments at June 30, 2020 and December 31, 2019: (in millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Level 1 Level 2 (1) June 30, 2020 U.S. government and agency bonds $ 60.1 $ 0.5 $ — $ 60.6 $ 60.6 $ — Corporate bonds 0.8 — — 0.8 — 0.8 Certificates of deposit 3.9 — — 3.9 — 3.9 Commercial Paper — — — — — — Total short-term investments $ 64.8 $ 0.5 $ — $ 65.3 $ 60.6 $ 4.7 U.S. government and agency bonds $ 20.7 $ 0.3 $ — $ 21.0 $ 15.4 $ 5.6 Corporate bonds 2.0 — — 2.0 — 2.0 Certificates of deposit 0.5 — — 0.5 — 0.5 Total long-term investments $ 23.2 $ 0.3 $ — $ 23.5 $ 15.4 $ 8.1 December 31, 2019 U.S. government and agency bonds $ 94.7 $ 0.3 $ — $ 95.0 $ 85.0 $ 10.0 Corporate bonds 51.0 0.1 — 51.1 — 51.1 Certificates of deposit 6.3 — — 6.3 — 6.3 Commercial Paper 10.0 — — 10.0 — 10.0 Total short-term investments $ 162.0 $ 0.4 $ — $ 162.4 $ 85.0 $ 77.4 U.S. government and agency bonds $ 52.9 $ 0.1 $ (0.1) $ 52.9 $ 42.9 $ 10.0 Corporate bonds 2.8 — — 2.8 — 2.8 Certificates of deposit 2.7 — — 2.7 — 2.7 Total long-term investments $ 58.4 $ 0.1 $ (0.1) $ 58.4 $ 42.9 $ 15.5 (1) Fair value was determined using market prices obtained from third-party pricing sources. |
Inventories
Inventories | 6 Months Ended |
Jun. 30, 2020 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories At the end of each period, inventories were comprised of the following: (in millions) June 30, 2020 December 31, 2019 Raw materials $ 33.7 $ 23.3 Work-in-process 37.2 40.3 Finished goods 32.8 37.4 Total inventories $ 103.7 $ 101.0 |
Goodwill and Other Intangible A
Goodwill and Other Intangible Assets, Net | 6 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Other Intangible Assets, Net | Goodwill and Other Intangible Assets, Net The change in the carrying amount of goodwill for the six months ended June 30, 2020 was as follows: (in millions) Goodwill at December 31, 2019 $ 39.8 Foreign currency translation (0.2) Goodwill at June 30, 2020 $ 39.6 The gross carrying amount, accumulated amortization and net book value of intangible assets at the end of each period were as follows: June 30, 2020 December 31, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Net Book Gross Carrying Amount Accumulated Amortization Net Book Customer relationships (1) $ 9.9 $ (3.3) $ 6.6 $ 9.9 $ (2.8) $ 7.1 Internal-use software 11.2 (7.8) 3.4 12.0 (6.8) 5.2 Intellectual property 1.0 (0.1) 0.9 1.0 (0.1) 0.9 Total $ 22.1 $ (11.2) $ 10.9 $ 22.9 $ (9.7) $ 13.2 (1) Includes customer relationships acquired from the Company’s former European distributor. See Note 9. Amortization expense for intangible assets was $0.7 million and $0.6 million for the three months ended June 30, 2020 and 2019, respectively. Amortization expense for intangible assets was $1.5 million and $1.2 million for the six months ended June 30, 2020, and 2019, respectively. Amortization expense associated with intangible assets included on the Company’s balance sheet as of June 30, 2020 is expected to be as follows: Years Ending December 31, (in millions) 2020 (remaining) $ 1.3 2021 2.2 2022 1.6 2023 1.2 2024 1.1 Thereafter 3.5 Total $ 10.9 |
Convertible Debt, Net
Convertible Debt, Net | 6 Months Ended |
Jun. 30, 2020 | |
Debt Disclosure [Abstract] | |
Convertible Debt, Net | Convertible Debt, Net The components of outstanding convertible debt consisted of the following: (in millions) June 30, 2020 December 31, 2019 1.375% Convertible Senior Notes, due November 2024 $ 402.5 $ 402.5 0.375% Convertible Senior Notes, due September 2026 800.0 800.0 Unamortized debt discount (274.0) (294.8) Debt issuance costs (18.3) (19.8) Total convertible debt, net $ 910.2 $ 887.9 The carrying amount and the estimated fair value of the Company’s convertible debt, which is based on the Level 2 quoted market prices, were as follows: June 30, 2020 December 31, 2019 (in millions) Carrying Value Estimated Fair Value (1) Carrying Value Estimated Fair Value (1) 1.375% Convertible Senior Notes, due November 2024 $ 315.2 $ 512.8 $ 306.9 $ 512.8 0.375% Convertible Senior Notes, due September 2026 595.0 867.0 581.0 840.0 Total $ 910.2 $ 1,379.8 $ 887.9 $ 1,352.8 (1) Fair value was determined using market prices obtained from third-party pricing sources. |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 6 Months Ended |
Jun. 30, 2020 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Other Current Liabilities | Accrued Expenses and Other Current Liabilities The components of accrued expenses and other current liabilities were as follows: (in millions) June 30, 2020 December 31, 2019 Employee compensation and related costs $ 32.6 $ 45.9 Accrued rebates 10.3 7.5 Supplier purchases 4.7 2.4 Value added taxes payable 3.9 1.8 Deferred revenue 5.0 3.2 Other 42.3 42.4 Accrued expenses and other current liabilities $ 98.8 $ 103.2 Product Warranty Costs The Company provides a four-year warranty on Personal Diabetes Managers (“PDMs”) sold in the United States and Europe and a five-year warranty on PDMs sold in Canada and may replace Pods that do not function in accordance with product specifications. The Company estimates its warranty at the time the product is shipped based on historical experience and the estimated cost to service the claims. Since the Company continues to introduce new products and versions, the anticipated performance of the product over the warranty period is also considered in estimating warranty reserves. Warranty expense is recorded in cost of revenue in the consolidated statements of operations. Cost to service the claims reflects the current product cost. The following table is a summary of the activity related to the Company’s product warranty liability: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Product warranty liability at beginning of period $ 8.3 $ 6.3 $ 8.5 $ 6.4 Warranty expense 2.7 3.1 5.2 5.3 Warranty claims settled (2.9) (2.8) (5.6) (5.1) Product warranty liability at the end of period $ 8.1 $ 6.6 $ 8.1 $ 6.6 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Legal Proceedings Between May 5, 2015 and June 16, 2015, three class action lawsuits were filed by shareholders in the U.S. District Court, for the District of Massachusetts, against the Company and certain then current and former executives of the Company. Two suits subsequently were voluntarily dismissed. Arkansas Teacher Retirement System v. Insulet, et al., 1:15-cv-12345, (“ATRS”) alleged that the Company (and certain then current and former executives) committed violations of Sections 10(b) and 20(a) and Rule 10b-5 of the Securities Exchange Act of 1934 by making allegedly false and misleading statements about the Company’s business, operations and prospects. On February 8, 2018, the parties executed a binding stipulation of settlement, under which all claims were released, and a payment was made into an escrow account for the plaintiffs and the class they purport to represent. On August 6, 2018, the Court issued an order approving the settlement, but took the plaintiffs’ motion for fees and expenses under advisement, which motion remains pending. The Company had previously accrued fees and expenses in connection with this matter for the amount of the final settlement liability that was not covered by insurance, the amount of which was not material to the Company’s consolidated financial statements. In addition, on April 26, 2017, a derivative action (Walker v. DeSisto, et al., 1:17-cv-10738) (“Walker”) was filed, and on October 13, 2017, a second derivative action (Carnazza v. DeSisto, et al., 1:17-cv-11977) (“Carnazza”) was filed, both on behalf of the Company, each by a shareholder in the U.S. District Court for the District of Massachusetts against the Company (as a nominal defendant) and certain individual then current and former officers and directors of the Company. The allegations in the actions are substantially similar to those alleged in the securities class action. The actions seek, among other things, damages, disgorgement of certain types of compensation or profits, and attorneys’ fees and costs. On July 11, 2018, the parties executed a binding stipulation of settlement, under which all claims were released, and a payment of attorneys’ fees and reimbursement of expenses will be paid to plaintiffs’ counsel, subject to the Court’s approval. On July 13, 2018, the plaintiffs filed a motion for preliminary approval of the settlement, which is pending. The Company expects that such fees and expenses payable to plaintiff’s counsel will be covered by the Company’s insurance. In June 2020, Roche Diabetes Care, Inc. (“Roche”) filed a patent infringement lawsuit against the Company in the United States District Court for the District of Delaware alleging that the Company’s manufacture and sale of its Omnipod Insulin Management System, Omnipod Starter Kit and Omnipod 10 Pod Pack in the United States infringed Roche’s now-expired U.S. Patent 7,931,613. Roche is seeking monetary damages and attorneys’ fees and costs. Since the patent expired in 2019, Roche is not seeking injunctive relief and the lawsuit will have no impact on ongoing sales of the Company’s products. The Company believes that it has meritorious defenses to Roche’s claims and intends to vigorously defend against them. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or range of estimates, of potential losses. The court has not yet set a schedule for the case. In July 2020, the Company filed a patent infringement claim against Roche Diabetes Care Limited (“Roche Ltd.”) in the United Kingdom alleging that Roche Ltd.’s manufacture and sale of the Accu-Chek® Solo insulin pump and its consumable components infringes European Patent No. 1 335 764 in the United Kingdom. The Company is seeking an injunction to last until expiry of the patent and monetary damages. The Company is, from time to time, involved in the normal course of business in various legal proceedings, including intellectual property, contract, employment and product liability suits. Other than as described above, the Company does not expect the outcome of these proceedings, either individually or in the aggregate, to have a material adverse effect on its results of operations. Fees to Former European Distributor Following the expiration of an agreement with a former European distributor on June 30, 2018, the Company was required to pay a quarterly per-unit fee for Omnipod sales to certain customers of the former European distributor for a one-year period through June 30, 2019. The Company recognized a liability and an associated intangible asset for this fee as qualifying sales occurred. The methodology applicable for determining the total fee under the distribution agreement is subject to an active arbitration proceeding in Switzerland. The final amount of the fee could vary significantly depending on the number of customers who count for purposes of calculating the fee under the terms of the agreement. The Company estimates that the final aggregate fee is in the range of $5 million to $55 million . As of both June 30, 2020 and December 31, 2019, the Company had $2.7 million accrued related to this matter. The associated gross intangible asset was $7.8 million at both June 30, 2020 and December 31, 2019. |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Loss | 6 Months Ended |
Jun. 30, 2020 | |
Equity [Abstract] | |
Accumulated Other Comprehensive Loss | Accumulated Other Comprehensive Loss Changes in the components of accumulated other comprehensive loss, net of tax, were as follows: Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 (in millions) Foreign Currency Translation Adjustment Unrealized Gain on Available-for-sale Securities Accumulated Other Comprehensive Loss Foreign Currency Translation Adjustment Unrealized Gain on Available-for-sale Securities Accumulated Other Comprehensive Loss Balance at beginning of period $ (5.0) $ 1.2 $ (3.8) $ (1.6) $ 0.4 $ (1.2) Other comprehensive income (loss) 0.6 (0.4) 0.2 (2.8) 0.4 (2.4) Balance at the end of period $ (4.4) $ 0.8 $ (3.6) $ (4.4) $ 0.8 $ (3.6) Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 (in millions) Foreign Currency Translation Adjustment Unrealized Gain on Available-for-sale Securities Accumulated Other Comprehensive Loss Foreign Currency Translation Adjustment Unrealized Gain on Available-for-sale Securities Accumulated Other Comprehensive Loss Balance at beginning of period $ (3.0) $ (0.1) $ (3.1) $ (2.2) $ (0.7) $ (2.9) Other comprehensive income (0.4) 0.7 0.3 (1.2) 1.3 0.1 Balance at the end of period $ (3.4) $ 0.6 $ (2.8) $ (3.4) $ 0.6 $ (2.8) |
Interest Expense
Interest Expense | 6 Months Ended |
Jun. 30, 2020 | |
Other Income and Expenses [Abstract] | |
Interest Expense | Interest Expense Interest expense, net was as follows: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Contractual coupon interest $ 2.2 $ 2.5 $ 4.3 $ 4.9 Accretion of debt discount 10.5 7.1 20.9 14.0 Amortization of debt issuance costs 0.7 0.7 1.4 1.4 Capitalized interest (1.6) (2.6) (3.2) (6.0) Interest expense, net of portion capitalized 11.8 7.7 23.4 14.3 Interest income (0.7) (1.9) (2.2) (3.7) Interest expense, net $ 11.1 $ 5.8 $ 21.2 $ 10.6 |
Stock-Based Compensation
Stock-Based Compensation | 6 Months Ended |
Jun. 30, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Stock-Based Compensation | Stock-Based Compensation Compensation expense related to stock-based awards was recorded as follows: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Cost of revenue $ 0.1 $ 0.3 $ 0.2 $ 0.6 Research and development expenses 2.3 2.4 5.0 4.2 Selling, general and administrative expenses 3.4 5.6 8.5 9.3 Total $ 5.8 $ 8.3 $ 13.7 $ 14.1 |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The Company’s effective tax rate for the three and six months ended June 30, 2020 was 17.2% and 17.0%, compared with 25.6% and 12.3% for the three and six months ended June 30, 2019. Income tax benefits have not been recorded for losses in jurisdictions where valuation allowances exist against net deferred tax assets, primarily in the United States. As of June 30, 2020 and December 31, 2019, the Company maintained a full valuation allowance against its U.S. net deferred tax assets based on the determination that it is not more likely than not these future benefits will be realized. The Company had no uncertain tax positions at both June 30, 2020 and December 31, 2019. In April 2020, new interpretations of a German tax law related to intellectual property and withholding tax were released. The Company is evaluating whether these new interpretations, applicable to corporate multinationals, will have an impact on the consolidated financial statements. |
Net Income Per Share
Net Income Per Share | 6 Months Ended |
Jun. 30, 2020 | |
Earnings Per Share [Abstract] | |
Net Income Per Share | Net Income Per Share Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted net income per share is computed using the weighted average number of common shares outstanding and, when dilutive, common share equivalents from outstanding stock options and restricted stock units (using the treasury-stock method), and potential common shares from the Company’s convertible notes (using the if-converted method). The weighted-average number of common shares used in the computation of basic and diluted net income per share were as follows: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Weighted average number of common shares outstanding, basic 64,370,791 59,844,991 63,627,231 59,601,365 Stock options 1,086,474 1,479,713 1,129,985 1,513,886 Restricted stock units 121,248 161,621 212,971 217,200 Weighted average number of common shares outstanding, diluted 65,578,513 61,486,325 64,970,187 61,332,451 The number of common share equivalents excluded from the computation of diluted net income per share because either the effect would have been anti-dilutive, or the performance criteria related to the units had not yet been met, were as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 1.25% Convertible Senior Notes — 5,910,954 — 5,910,954 1.375% Convertible Senior Notes 4,319,429 4,319,429 4,319,429 4,319,429 0.375% Convertible Senior Notes 3,528,400 — 3,528,400 — Unvested restricted stock units 298,600 426,550 356,577 421,776 Stock options 66,855 181,132 52,069 231,289 Total 8,213,284 10,838,065 8,256,475 10,883,448 |
Basis of Presentation and Sum_2
Basis of Presentation and Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying financial statements reflect the consolidated operations of Insulet Corporation and its subsidiaries (“Insulet” or the “Company”). The unaudited consolidated financial statements have been prepared in United States dollars, in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the consolidated financial statements in conformity with GAAP requires management to make use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. Actual results may differ from those estimates. In management’s opinion, the unaudited consolidated financial statements contain all normal recurring adjustments necessary for a fair statement of the interim results reported. Operating results for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2020, or for any other subsequent interim period. The year-end balance sheet data was derived from audited consolidated financial statements. These unaudited consolidated financial statements do not include all of the annual disclosures required by GAAP; accordingly, they should be read in conjunction with the Company’s audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. |
Accounts Receivable and Allowance for Credit Losses | Accounts Receivable and Allowance for Credit Losses Trade accounts receivable consist of amounts due from third-party payors, customers and intermediaries and are presented at amortized cost. The allowance for credit losses reflects an estimate of losses inherent in the Company’s accounts receivable portfolio determined based on historical experience, specific allowances for known troubled accounts and other available evidence. Accounts receivable are written off when management determines they are uncollectable. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist. The Company has identified the following portfolio segments and measures the allowance for credit losses using the following methods: Direct Customer Receivables —The Company measures expected credit losses on direct customer receivables using an aging methodology. The risk of loss for direct customer receivables is higher than other portfolios. The Company relies on third-party payors to accept and timely process claims and on direct consumers to have the ability to pay. The estimate of expected credit losses considers historical credit loss information that is adjusted for current conditions and supportable forecasts. Distributor Receivables —The Company measures expected credit losses on distributor receivables using an individual reserve methodology. The risk of loss in this portfolio is low based on the Company’s historical experience. The estimate of expected credit losses considers payment history as well as credit ratings of the distributors, in addition to current conditions and supportable forecasts. |
Shipping and Handling costs | Shipping and Handling Costs Shipping and handling costs are included in selling, general and administrative expenses and were $1.9 million and $2.3 million for the three months ended June 30, 2020 and 2019, respectively, and were $3.8 million and $4.9 million for the six months ended June 30, 2020 and 2019, respectively. |
Fair Value Measurements | Fair Value Measurements Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. To measure fair value of assets and liabilities, the Company uses the following fair value hierarchy based on three levels of inputs: Level 1—observable inputs, such as quoted prices in active markets for identical assets or liabilities; Level 2—significant other observable inputs that are observable either directly or indirectly; and Level 3—significant unobservable inputs for which there are little or no market data, which require the Company to develop its own assumptions. |
Reclassification of Prior Period Amounts | Reclassification of Prior Period AmountsCertain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation. A portion of facility costs and certain information technology costs have been allocated from selling, general and administrative to research and development expenses based on square foot and system usage, respectively. In addition, certain quality assurance costs were reclassified from research and development expenses to selling, general and administrative expenses. |
Recently Adopted Accounting Standards | Recently Adopted Accounting Standards Effective January 1, 2020, the Company adopted Accounting Standards Update (“ASU”) 2016-13, Credit Losses (Topic 326) (“ASU 2016-13”). ASU 2016-13 requires financial assets measured at amortized cost, such as the Company’s trade receivables and contract assets, to be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions and future expectation for each pool of similar financial assets. The new guidance also requires enhanced disclosures related to trade receivables and associated credit losses. The Company adopted ASU 2016-13 using the modified retrospective method, whereby the guidance is applied prospectively as of the date of adoption and prior periods are not restated. The cumulative effect of adopting ASU 2016-13 The following table presents the activity in the allowance for credit losses for the three and six months ended June 30, 2020 , comprised primarily of our direct consumer receivable portfolio. The allowance for credit losses of other portfolios is insignificant. (in millions) Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Credit losses at the beginning of the period $ 4.1 $ 3.8 Effect of adoption — 1.1 Credit losses at the beginning of the period after adoption 4.1 4.9 Provision for expected credit losses 2.0 2.6 Write-offs charged against allowance (1.6) (3.1) Recoveries of amounts previously written-off 0.1 0.2 Credit losses at the end of the period $ 4.6 $ 4.6 Effective January 1, 2020, the Company adopted ASU 2017-04, Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). ASU 2017-04 requires an entity to measure the impairment of goodwill assigned to a reporting unit as the amount by which the carrying value of the assets and liabilities of the reporting unit, including goodwill, exceeds the reporting units’ fair value. The adoption of this guidance had no impact on the consolidated financial statements. |
Product Warranty Costs | Product Warranty Costs The Company provides a four-year warranty on Personal Diabetes Managers (“PDMs”) sold in the United States and Europe and a five-year warranty |
Basis of Presentation and Sum_3
Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Allowance for Credit Loss | The following table presents the activity in the allowance for credit losses for the three and six months ended June 30, 2020 , comprised primarily of our direct consumer receivable portfolio. The allowance for credit losses of other portfolios is insignificant. (in millions) Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Credit losses at the beginning of the period $ 4.1 $ 3.8 Effect of adoption — 1.1 Credit losses at the beginning of the period after adoption 4.1 4.9 Provision for expected credit losses 2.0 2.6 Write-offs charged against allowance (1.6) (3.1) Recoveries of amounts previously written-off 0.1 0.2 Credit losses at the end of the period $ 4.6 $ 4.6 |
Revenue and Contract Acquisit_2
Revenue and Contract Acquisition Costs (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Summary of Revenue from Contracts with Customers | The following table summarizes the Company’s disaggregated revenues: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 U.S. Omnipod $ 128.8 $ 98.1 $ 245.4 $ 184.2 International Omnipod 73.2 62.7 146.3 119.6 Total Omnipod 202.0 160.8 391.7 303.8 Drug Delivery 24.3 16.3 32.6 32.9 Total $ 226.3 $ 177.1 $ 424.3 $ 336.7 |
Summary of Deferred Revenue | Deferred revenue related to unsatisfied performance obligations was included in the following consolidated balance sheet accounts in the amounts shown: (in millions) June 30, 2020 December 31, 2019 Accrued expenses and other current liabilities $ 5.0 $ 3.2 Other liabilities 0.9 1.0 Total deferred revenue $ 5.9 $ 4.2 |
Summary of Contract Acquisition Costs | Contract acquisition costs, representing capitalized commission costs related to new customers, net of amortization, were included in the following consolidated balance sheet captions in the amounts shown: (in millions) June 30, 2020 December 31, 2019 Prepaid expenses and other current assets $ 9.9 $ 9.5 Other assets 19.7 19.9 Total capitalized contract acquisition costs, net $ 29.6 $ 29.4 |
Cash and Cash Equivalents (Tabl
Cash and Cash Equivalents (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Cash and Cash Equivalents [Abstract] | |
Summary of Cash and Cash Equivalents | The following table provides a summary of cash and cash equivalents and the level in the fair value hierarchy in which those measurements fall: June 30, 2020 December 31, 2019 (in millions) Total Level 1 Level 2 Total Level 1 Level 2 (1) Cash $ 470.3 $ 470.3 $ — $ 85.3 $ 85.3 $ — Money market mutual funds 305.9 305.9 — 115.5 115.5 — Commercial paper — — — 10.0 — 10.0 Restricted cash 2.9 2.9 — 2.9 2.9 — Total cash and cash equivalents $ 779.1 $ 779.1 $ — $ 213.7 $ 203.7 $ 10.0 (1) Fair value was determined using market prices obtained from third-party pricing sources. |
Summary of Restricted Cash and Cash Equivalents | The following table provides a summary of cash and cash equivalents and the level in the fair value hierarchy in which those measurements fall: June 30, 2020 December 31, 2019 (in millions) Total Level 1 Level 2 Total Level 1 Level 2 (1) Cash $ 470.3 $ 470.3 $ — $ 85.3 $ 85.3 $ — Money market mutual funds 305.9 305.9 — 115.5 115.5 — Commercial paper — — — 10.0 — 10.0 Restricted cash 2.9 2.9 — 2.9 2.9 — Total cash and cash equivalents $ 779.1 $ 779.1 $ — $ 213.7 $ 203.7 $ 10.0 (1) Fair value was determined using market prices obtained from third-party pricing sources. |
Investments (Tables)
Investments (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Investments, Debt and Equity Securities [Abstract] | |
Summary of Amortized Cost, Gross Unrealized Gains and Losses, Fair Value and Level in Fair Value Hierarchy for Investments | The following table provides amortized costs, gross unrealized gains and losses, fair values and the level in the fair value hierarchy for the Company’s investments at June 30, 2020 and December 31, 2019: (in millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Level 1 Level 2 (1) June 30, 2020 U.S. government and agency bonds $ 60.1 $ 0.5 $ — $ 60.6 $ 60.6 $ — Corporate bonds 0.8 — — 0.8 — 0.8 Certificates of deposit 3.9 — — 3.9 — 3.9 Commercial Paper — — — — — — Total short-term investments $ 64.8 $ 0.5 $ — $ 65.3 $ 60.6 $ 4.7 U.S. government and agency bonds $ 20.7 $ 0.3 $ — $ 21.0 $ 15.4 $ 5.6 Corporate bonds 2.0 — — 2.0 — 2.0 Certificates of deposit 0.5 — — 0.5 — 0.5 Total long-term investments $ 23.2 $ 0.3 $ — $ 23.5 $ 15.4 $ 8.1 December 31, 2019 U.S. government and agency bonds $ 94.7 $ 0.3 $ — $ 95.0 $ 85.0 $ 10.0 Corporate bonds 51.0 0.1 — 51.1 — 51.1 Certificates of deposit 6.3 — — 6.3 — 6.3 Commercial Paper 10.0 — — 10.0 — 10.0 Total short-term investments $ 162.0 $ 0.4 $ — $ 162.4 $ 85.0 $ 77.4 U.S. government and agency bonds $ 52.9 $ 0.1 $ (0.1) $ 52.9 $ 42.9 $ 10.0 Corporate bonds 2.8 — — 2.8 — 2.8 Certificates of deposit 2.7 — — 2.7 — 2.7 Total long-term investments $ 58.4 $ 0.1 $ (0.1) $ 58.4 $ 42.9 $ 15.5 (1) Fair value was determined using market prices obtained from third-party pricing sources. |
Inventories (Tables)
Inventories (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Inventory Disclosure [Abstract] | |
Components of Inventories | At the end of each period, inventories were comprised of the following: (in millions) June 30, 2020 December 31, 2019 Raw materials $ 33.7 $ 23.3 Work-in-process 37.2 40.3 Finished goods 32.8 37.4 Total inventories $ 103.7 $ 101.0 |
Goodwill and Other Intangible_2
Goodwill and Other Intangible Assets, Net (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Summary of Changes in Carrying Amounts of Goodwill | The change in the carrying amount of goodwill for the six months ended June 30, 2020 was as follows: (in millions) Goodwill at December 31, 2019 $ 39.8 Foreign currency translation (0.2) Goodwill at June 30, 2020 $ 39.6 |
Components of Other Intangible Assets | The gross carrying amount, accumulated amortization and net book value of intangible assets at the end of each period were as follows: June 30, 2020 December 31, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Net Book Gross Carrying Amount Accumulated Amortization Net Book Customer relationships (1) $ 9.9 $ (3.3) $ 6.6 $ 9.9 $ (2.8) $ 7.1 Internal-use software 11.2 (7.8) 3.4 12.0 (6.8) 5.2 Intellectual property 1.0 (0.1) 0.9 1.0 (0.1) 0.9 Total $ 22.1 $ (11.2) $ 10.9 $ 22.9 $ (9.7) $ 13.2 (1) Includes customer relationships acquired from the Company’s former European distributor. See Note 9. |
Amortization Expense Expected for Next Five Years | Amortization expense associated with intangible assets included on the Company’s balance sheet as of June 30, 2020 is expected to be as follows: Years Ending December 31, (in millions) 2020 (remaining) $ 1.3 2021 2.2 2022 1.6 2023 1.2 2024 1.1 Thereafter 3.5 Total $ 10.9 |
Convertible Debt, Net (Tables)
Convertible Debt, Net (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Debt Disclosure [Abstract] | |
Outstanding Convertible Debt and Related Debt Issuance Costs | The components of outstanding convertible debt consisted of the following: (in millions) June 30, 2020 December 31, 2019 1.375% Convertible Senior Notes, due November 2024 $ 402.5 $ 402.5 0.375% Convertible Senior Notes, due September 2026 800.0 800.0 Unamortized debt discount (274.0) (294.8) Debt issuance costs (18.3) (19.8) Total convertible debt, net $ 910.2 $ 887.9 |
Summary of Carrying Amount and Estimated Fair Value of Convertible Debt | The carrying amount and the estimated fair value of the Company’s convertible debt, which is based on the Level 2 quoted market prices, were as follows: June 30, 2020 December 31, 2019 (in millions) Carrying Value Estimated Fair Value (1) Carrying Value Estimated Fair Value (1) 1.375% Convertible Senior Notes, due November 2024 $ 315.2 $ 512.8 $ 306.9 $ 512.8 0.375% Convertible Senior Notes, due September 2026 595.0 867.0 581.0 840.0 Total $ 910.2 $ 1,379.8 $ 887.9 $ 1,352.8 (1) Fair value was determined using market prices obtained from third-party pricing sources. |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Payables and Accruals [Abstract] | |
Components of Accrued Expenses and Other Current Liabilities | The components of accrued expenses and other current liabilities were as follows: (in millions) June 30, 2020 December 31, 2019 Employee compensation and related costs $ 32.6 $ 45.9 Accrued rebates 10.3 7.5 Supplier purchases 4.7 2.4 Value added taxes payable 3.9 1.8 Deferred revenue 5.0 3.2 Other 42.3 42.4 Accrued expenses and other current liabilities $ 98.8 $ 103.2 |
Reconciliation of Changes in Product Warranty Liability | The following table is a summary of the activity related to the Company’s product warranty liability: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Product warranty liability at beginning of period $ 8.3 $ 6.3 $ 8.5 $ 6.4 Warranty expense 2.7 3.1 5.2 5.3 Warranty claims settled (2.9) (2.8) (5.6) (5.1) Product warranty liability at the end of period $ 8.1 $ 6.6 $ 8.1 $ 6.6 |
Accumulated Other Comprehensi_2
Accumulated Other Comprehensive Loss (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Equity [Abstract] | |
Schedule of Accumulated Other Comprehensive Income | Changes in the components of accumulated other comprehensive loss, net of tax, were as follows: Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 (in millions) Foreign Currency Translation Adjustment Unrealized Gain on Available-for-sale Securities Accumulated Other Comprehensive Loss Foreign Currency Translation Adjustment Unrealized Gain on Available-for-sale Securities Accumulated Other Comprehensive Loss Balance at beginning of period $ (5.0) $ 1.2 $ (3.8) $ (1.6) $ 0.4 $ (1.2) Other comprehensive income (loss) 0.6 (0.4) 0.2 (2.8) 0.4 (2.4) Balance at the end of period $ (4.4) $ 0.8 $ (3.6) $ (4.4) $ 0.8 $ (3.6) Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 (in millions) Foreign Currency Translation Adjustment Unrealized Gain on Available-for-sale Securities Accumulated Other Comprehensive Loss Foreign Currency Translation Adjustment Unrealized Gain on Available-for-sale Securities Accumulated Other Comprehensive Loss Balance at beginning of period $ (3.0) $ (0.1) $ (3.1) $ (2.2) $ (0.7) $ (2.9) Other comprehensive income (0.4) 0.7 0.3 (1.2) 1.3 0.1 Balance at the end of period $ (3.4) $ 0.6 $ (2.8) $ (3.4) $ 0.6 $ (2.8) |
Interest Expense (Tables)
Interest Expense (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Other Income and Expenses [Abstract] | |
Summary of Interest and Other Expense | Interest expense, net was as follows: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Contractual coupon interest $ 2.2 $ 2.5 $ 4.3 $ 4.9 Accretion of debt discount 10.5 7.1 20.9 14.0 Amortization of debt issuance costs 0.7 0.7 1.4 1.4 Capitalized interest (1.6) (2.6) (3.2) (6.0) Interest expense, net of portion capitalized 11.8 7.7 23.4 14.3 Interest income (0.7) (1.9) (2.2) (3.7) Interest expense, net $ 11.1 $ 5.8 $ 21.2 $ 10.6 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Summary of Share-Based Compensation Expense | Compensation expense related to stock-based awards was recorded as follows: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Cost of revenue $ 0.1 $ 0.3 $ 0.2 $ 0.6 Research and development expenses 2.3 2.4 5.0 4.2 Selling, general and administrative expenses 3.4 5.6 8.5 9.3 Total $ 5.8 $ 8.3 $ 13.7 $ 14.1 |
Net Income Per Share (Tables)
Net Income Per Share (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Earnings Per Share [Abstract] | |
Computation of Basic and Diluted Net Income (Loss) per Share | The weighted-average number of common shares used in the computation of basic and diluted net income per share were as follows: Three Months Ended June 30, Six Months Ended June 30, (in millions) 2020 2019 2020 2019 Weighted average number of common shares outstanding, basic 64,370,791 59,844,991 63,627,231 59,601,365 Stock options 1,086,474 1,479,713 1,129,985 1,513,886 Restricted stock units 121,248 161,621 212,971 217,200 Weighted average number of common shares outstanding, diluted 65,578,513 61,486,325 64,970,187 61,332,451 |
Potential Common Share Equivalents Excluded from Computation of Diluted Net Income (Loss) per Share | The number of common share equivalents excluded from the computation of diluted net income per share because either the effect would have been anti-dilutive, or the performance criteria related to the units had not yet been met, were as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 1.25% Convertible Senior Notes — 5,910,954 — 5,910,954 1.375% Convertible Senior Notes 4,319,429 4,319,429 4,319,429 4,319,429 0.375% Convertible Senior Notes 3,528,400 — 3,528,400 — Unvested restricted stock units 298,600 426,550 356,577 421,776 Stock options 66,855 181,132 52,069 231,289 Total 8,213,284 10,838,065 8,256,475 10,883,448 |
Basis of Presentation and Sum_4
Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Significant Accounting Policies [Line Items] | |||||
Cost of revenue | $ 83.8 | $ 60.7 | $ 154.9 | $ 113.6 | |
Accounting Standards Update [Extensible List] | us-gaap:AccountingStandardsUpdate201613Member | ||||
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | |||||
Beginning balance | 4.1 | 3.8 | |||
Provision for expected credit losses | 2 | 2.6 | 2 | ||
Write-offs charged against allowance | (1.6) | (3.1) | |||
Recoveries of amounts previously written-off | 0.1 | 0.2 | |||
Ending balance | 4.6 | 4.6 | $ 3.8 | ||
Cumulative Effect, Period of Adoption, Adjusted Balance | |||||
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | |||||
Beginning balance | 4.1 | 4.9 | |||
Ending balance | 4.9 | ||||
Cumulative Effect, Period of Adoption, Adjustment | |||||
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | |||||
Beginning balance | 0 | 1.1 | |||
Ending balance | 1.1 | ||||
Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit | |||||
Significant Accounting Policies [Line Items] | |||||
Increase of accumulated deficit | $ 1.1 | ||||
Accounts and unbilled receivables | |||||
Significant Accounting Policies [Line Items] | |||||
Reclassification of prior period amounts | (1.6) | ||||
Prepaid expenses and other assets | |||||
Significant Accounting Policies [Line Items] | |||||
Reclassification of prior period amounts | (1.6) | ||||
Selling, general and administrative expenses | |||||
Significant Accounting Policies [Line Items] | |||||
Reclassification of prior period amounts | 0.7 | 1.3 | |||
Research and development expenses | |||||
Significant Accounting Policies [Line Items] | |||||
Reclassification of prior period amounts | 0.7 | 1.3 | |||
Shipping and Handling | |||||
Significant Accounting Policies [Line Items] | |||||
Cost of revenue | $ 1.9 | $ 2.3 | $ 3.8 | $ 4.9 |
Revenue and Contract Acquisit_3
Revenue and Contract Acquisition Costs - Summary of Revenue from Contracts with Customers (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Disaggregation of Revenue [Line Items] | ||||
Revenue | $ 226.3 | $ 177.1 | $ 424.3 | $ 336.7 |
U.S. Omnipod | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 128.8 | 98.1 | 245.4 | 184.2 |
International Omnipod | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 73.2 | 62.7 | 146.3 | 119.6 |
Total Omnipod | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 202 | 160.8 | 391.7 | 303.8 |
Drug Delivery | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | $ 24.3 | $ 16.3 | $ 32.6 | $ 32.9 |
Customer 1 | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue, percentage | 21.00% | 12.00% | 21.00% | 12.00% |
Customer 2 | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue, percentage | 21.00% | 21.00% | 21.00% | 21.00% |
Revenue and Contract Acquisit_4
Revenue and Contract Acquisition Costs - Summary of Deferred Revenue (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Revenue from Contract with Customer [Abstract] | ||
Accrued expenses and other current liabilities | $ 5 | $ 3.2 |
Other liabilities | 0.9 | 1 |
Total deferred revenue | $ 5.9 | $ 4.2 |
Revenue and Contract Acquisit_5
Revenue and Contract Acquisition Costs - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Revenue from Contract with Customer [Abstract] | |||||
Revenue recognized | $ 0.1 | $ 0.2 | $ 1.6 | $ 1.1 | |
Unbilled receivable | 22.3 | 22.3 | $ 13.5 | ||
Amortization of capitalized commission costs | $ 2.6 | $ 2.1 | $ 5.1 | $ 4.1 |
Revenue and Contract Acquisit_6
Revenue and Contract Acquisition Costs - Summary of Contract Acquisition Costs (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Revenue from Contract with Customer [Abstract] | ||
Prepaid expenses and other current assets | $ 9.9 | $ 9.5 |
Other assets | 19.7 | 19.9 |
Total capitalized contract acquisition costs, net | $ 29.6 | $ 29.4 |
Cash and Cash Equivalents (Deta
Cash and Cash Equivalents (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | $ 779.1 | $ 213.7 |
Cash | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 470.3 | 85.3 |
Money market mutual funds | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 305.9 | 115.5 |
Commercial Paper | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 0 | 10 |
Restricted cash | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 2.9 | 2.9 |
Level 1 | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 779.1 | 203.7 |
Level 1 | Cash | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 470.3 | 85.3 |
Level 1 | Money market mutual funds | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 305.9 | 115.5 |
Level 1 | Commercial Paper | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 0 | 0 |
Level 1 | Restricted cash | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 2.9 | 2.9 |
Level 2 | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 0 | 10 |
Level 2 | Cash | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 0 | 0 |
Level 2 | Money market mutual funds | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 0 | 0 |
Level 2 | Commercial Paper | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | 0 | 10 |
Level 2 | Restricted cash | ||
Cash and Cash Equivalents [Line Items] | ||
Total cash and cash equivalents | $ 0 | $ 0 |
Investments - Narrative (Detail
Investments - Narrative (Details) | 6 Months Ended |
Jun. 30, 2020 | |
Minimum | |
Debt Securities, Available-for-sale [Line Items] | |
Derivative maturity date range | 1 month |
Maximum | |
Debt Securities, Available-for-sale [Line Items] | |
Derivative maturity date range | 2 years |
Investments - Summary of Amorti
Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, Fair Value and Level in Fair Value Hierarchy for Investments (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Short-term investments | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | $ 64.8 | $ 162 |
Gross Unrealized Gains | 0.5 | 0.4 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 65.3 | 162.4 |
Short-term investments | Level 1 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 60.6 | 85 |
Short-term investments | Level 2 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 4.7 | 77.4 |
Short-term investments | U.S. government and agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 60.1 | 94.7 |
Gross Unrealized Gains | 0.5 | 0.3 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 60.6 | 95 |
Short-term investments | U.S. government and agency bonds | Level 1 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 60.6 | 85 |
Short-term investments | U.S. government and agency bonds | Level 2 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 0 | 10 |
Short-term investments | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 0.8 | 51 |
Gross Unrealized Gains | 0 | 0.1 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 0.8 | 51.1 |
Short-term investments | Corporate bonds | Level 1 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 0 | 0 |
Short-term investments | Corporate bonds | Level 2 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 0.8 | 51.1 |
Short-term investments | Certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 3.9 | 6.3 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 3.9 | 6.3 |
Short-term investments | Certificates of deposit | Level 1 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 0 | 0 |
Short-term investments | Certificates of deposit | Level 2 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 3.9 | 6.3 |
Short-term investments | Commercial Paper | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 0 | 10 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 0 | 10 |
Short-term investments | Commercial Paper | Level 1 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 0 | 0 |
Short-term investments | Commercial Paper | Level 2 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 0 | 10 |
Long-term investments | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 23.2 | 58.4 |
Gross Unrealized Gains | 0.3 | 0.1 |
Gross Unrealized Losses | 0 | (0.1) |
Fair Value | 23.5 | 58.4 |
Long-term investments | Level 1 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 15.4 | 42.9 |
Long-term investments | Level 2 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 8.1 | 15.5 |
Long-term investments | U.S. government and agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 20.7 | 52.9 |
Gross Unrealized Gains | 0.3 | 0.1 |
Gross Unrealized Losses | 0 | (0.1) |
Fair Value | 21 | 52.9 |
Long-term investments | U.S. government and agency bonds | Level 1 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 15.4 | 42.9 |
Long-term investments | U.S. government and agency bonds | Level 2 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 5.6 | 10 |
Long-term investments | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 2 | 2.8 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 2 | 2.8 |
Long-term investments | Corporate bonds | Level 1 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 0 | 0 |
Long-term investments | Corporate bonds | Level 2 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 2 | 2.8 |
Long-term investments | Certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Amortized Cost | 0.5 | 2.7 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 0.5 | 2.7 |
Long-term investments | Certificates of deposit | Level 1 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | 0 | 0 |
Long-term investments | Certificates of deposit | Level 2 | Recurring fair value measurements | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair Value | $ 0.5 | $ 2.7 |
Inventories - Components of Inv
Inventories - Components of Inventories (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 33.7 | $ 23.3 |
Work-in-process | 37.2 | 40.3 |
Finished goods | 32.8 | 37.4 |
Total inventories | $ 103.7 | $ 101 |
Goodwill and Other Intangible_3
Goodwill and Other Intangible Assets, Net - Summary of Changes in Carrying Amounts of Goodwill (Details) $ in Millions | 6 Months Ended |
Jun. 30, 2020USD ($) | |
Goodwill [Roll Forward] | |
Goodwill at December 31, 2019 | $ 39.8 |
Foreign currency translation | (0.2) |
Goodwill at June 30, 2020 | $ 39.6 |
Goodwill and Other Intangible_4
Goodwill and Other Intangible Assets, Net - Components of Other Intangible Assets (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 22.1 | $ 22.9 |
Accumulated Amortization | (11.2) | (9.7) |
Net Book Value | 10.9 | 13.2 |
Customer relationships | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 9.9 | 9.9 |
Accumulated Amortization | (3.3) | (2.8) |
Net Book Value | 6.6 | 7.1 |
Internal-use software | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 11.2 | 12 |
Accumulated Amortization | (7.8) | (6.8) |
Net Book Value | 3.4 | 5.2 |
Intellectual property | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 1 | 1 |
Accumulated Amortization | (0.1) | (0.1) |
Net Book Value | $ 0.9 | $ 0.9 |
Goodwill and Other Intangible_5
Goodwill and Other Intangible Assets, Net - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||||
Amortization of other intangible assets | $ 0.7 | $ 0.6 | $ 1.5 | $ 1.2 |
Goodwill and Other Intangible_6
Goodwill and Other Intangible Assets, Net - Amortization Expense Expected for Next Five Years (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2020 (remaining) | $ 1.3 | |
2021 | 2.2 | |
2022 | 1.6 | |
2023 | 1.2 | |
2024 | 1.1 | |
Thereafter | 3.5 | |
Net Book Value | $ 10.9 | $ 13.2 |
Convertible Debt, Net - Outstan
Convertible Debt, Net - Outstanding Convertible Debt and Related Debt Issuance Costs (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 | Jun. 30, 2019 |
Debt Instrument [Line Items] | |||
Unamortized debt discount | $ (274) | $ (294.8) | |
Debt issuance costs | (18.3) | (19.8) | |
Total convertible debt, net | $ 910.2 | $ 887.9 | |
1.375% Convertible Senior Notes, due November 2024 | |||
Debt Instrument [Line Items] | |||
Debt, interest rate | 1.375% | 1.375% | 1.375% |
0.375% Convertible Senior Notes, due September 2026 | |||
Debt Instrument [Line Items] | |||
Debt, interest rate | 0.375% | 0.375% | 0.375% |
Convertible Debt | 1.375% Convertible Senior Notes, due November 2024 | |||
Debt Instrument [Line Items] | |||
Principal amount of Senior Notes | $ 402.5 | $ 402.5 | |
Convertible Debt | 0.375% Convertible Senior Notes, due September 2026 | |||
Debt Instrument [Line Items] | |||
Principal amount of Senior Notes | $ 800 | $ 800 |
Convertible Debt, Net - Summary
Convertible Debt, Net - Summary of Carrying Amount and Estimated Fair Value of Convertible Debt (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 | Jun. 30, 2019 |
1.375% Convertible Senior Notes, due November 2024 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Debt, interest rate | 1.375% | 1.375% | 1.375% |
0.375% Convertible Senior Notes, due September 2026 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Debt, interest rate | 0.375% | 0.375% | 0.375% |
Level 2 | Carrying Value | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial instrument value | $ 910.2 | $ 887.9 | |
Level 2 | Carrying Value | 1.375% Convertible Senior Notes, due November 2024 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial instrument value | 315.2 | 306.9 | |
Level 2 | Carrying Value | 0.375% Convertible Senior Notes, due September 2026 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial instrument value | 595 | 581 | |
Level 2 | Estimated Fair Value | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial instrument value | 1,379.8 | 1,352.8 | |
Level 2 | Estimated Fair Value | 1.375% Convertible Senior Notes, due November 2024 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial instrument value | 512.8 | 512.8 | |
Level 2 | Estimated Fair Value | 0.375% Convertible Senior Notes, due September 2026 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial instrument value | $ 867 | $ 840 |
Accrued Expenses and Other Cu_3
Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Dec. 31, 2019 |
Payables and Accruals [Abstract] | ||
Employee compensation and related costs | $ 32.6 | $ 45.9 |
Accrued rebates | 10.3 | 7.5 |
Supplier purchases | 4.7 | 2.4 |
Value added taxes payable | 3.9 | 1.8 |
Deferred revenue | 5 | 3.2 |
Other | 42.3 | 42.4 |
Accrued expenses and other current liabilities | $ 98.8 | $ 103.2 |
Accrued Expenses and Other Cu_4
Accrued Expenses and Other Current Liabilities - Narrative (Details) | 6 Months Ended |
Jun. 30, 2020 | |
United States | |
Product Warranty Liability [Line Items] | |
Product warranty term for PDMs | 4 years |
CANADA | |
Product Warranty Liability [Line Items] | |
Product warranty term for PDMs | 5 years |
Accrued Expenses and Other Cu_5
Accrued Expenses and Other Current Liabilities - Product Warranty Liability (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] | ||||
Product warranty liability at beginning of period | $ 8.3 | $ 6.3 | $ 8.5 | $ 6.4 |
Warranty expense | 2.7 | 3.1 | 5.2 | 5.3 |
Warranty claims settled | (2.9) | (2.8) | (5.6) | (5.1) |
Product warranty liability at the end of period | $ 8.1 | $ 6.6 | $ 8.1 | $ 6.6 |
Commitments and Contingencies -
Commitments and Contingencies - Narrative (Details) | 1 Months Ended | |||
Jun. 16, 2015lawsuit | Jun. 30, 2020USD ($) | Dec. 31, 2019USD ($) | Jun. 30, 2019USD ($) | |
Loss Contingencies [Line Items] | ||||
Number of class actions filed (in legal matters) | lawsuit | 3 | |||
Number of class actions dismissed (in legal matters) | lawsuit | 2 | |||
Fees To Former European Distributor | ||||
Loss Contingencies [Line Items] | ||||
Accrued liabilities | $ 2,700,000 | $ 2,700,000 | ||
Associated gross intangible asset | $ 7,800,000 | $ 7,800,000 | ||
Fees To Former European Distributor | Minimum | ||||
Loss Contingencies [Line Items] | ||||
Commitment due in next twelve months | $ 5,000,000 | |||
Fees To Former European Distributor | Maximum | ||||
Loss Contingencies [Line Items] | ||||
Commitment due in next twelve months | $ 55,000,000 |
Accumulated Other Comprehensi_3
Accumulated Other Comprehensive Income - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Accumulated Other Comprehensive Income [Line Items] | ||||
Beginning balance | $ 59 | $ 223.6 | $ 75.9 | $ 212.1 |
Other comprehensive income | 0.2 | 0.3 | (2.4) | 0.1 |
Ending balance | 563.3 | 249.8 | 563.3 | 249.8 |
Foreign Currency Translation Adjustment | ||||
Accumulated Other Comprehensive Income [Line Items] | ||||
Beginning balance | (5) | (3) | (1.6) | (2.2) |
Other comprehensive income | 0.6 | (0.4) | (2.8) | (1.2) |
Ending balance | (4.4) | (3.4) | (4.4) | (3.4) |
Unrealized Gain on Available-for-sale Securities | ||||
Accumulated Other Comprehensive Income [Line Items] | ||||
Beginning balance | 1.2 | (0.1) | 0.4 | (0.7) |
Other comprehensive income | (0.4) | 0.7 | 0.4 | 1.3 |
Ending balance | 0.8 | 0.6 | 0.8 | 0.6 |
Accumulated Other Comprehensive Loss | ||||
Accumulated Other Comprehensive Income [Line Items] | ||||
Beginning balance | (3.8) | (3.1) | (1.2) | (2.9) |
Other comprehensive income | 0.2 | 0.3 | (2.4) | 0.1 |
Ending balance | $ (3.6) | $ (2.8) | $ (3.6) | $ (2.8) |
Interest Expense - Interest Exp
Interest Expense - Interest Expense (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Debt Disclosure [Abstract] | ||||
Contractual coupon interest | $ 2.2 | $ 2.5 | $ 4.3 | $ 4.9 |
Accretion of debt discount | 10.5 | 7.1 | 20.9 | 14 |
Amortization of debt issuance costs | 0.7 | 0.7 | 1.4 | 1.4 |
Capitalized interest | (1.6) | (2.6) | (3.2) | (6) |
Interest expense, net of portion capitalized | 11.8 | 7.7 | 23.4 | 14.3 |
Interest income | (0.7) | (1.9) | (2.2) | (3.7) |
Interest expense, net | $ 11.1 | $ 5.8 | $ 21.2 | $ 10.6 |
Stock-Based Compensation - Sche
Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Share-Based Awards (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation expense | $ 5.8 | $ 8.3 | $ 13.7 | $ 14.1 |
Cost of revenue | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation expense | 0.1 | 0.3 | 0.2 | 0.6 |
Research and development expenses | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation expense | 2.3 | 2.4 | 5 | 4.2 |
Selling, general and administrative expenses | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation expense | $ 3.4 | $ 5.6 | $ 8.5 | $ 9.3 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Income Tax Disclosure [Abstract] | ||||
Effective tax rate | 17.20% | 25.60% | 17.00% | 12.30% |
Net Income Per Share - Computat
Net Income Per Share - Computation of Basic and Diluted Net Income per Share (Details) - shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Weighted average number of common shares outstanding, basic (in shares) | 64,370,791 | 59,844,991 | 63,627,231 | 59,601,365 |
Weighted average number of common shares outstanding, diluted (in shares) | 65,578,513 | 61,486,325 | 64,970,187 | 61,332,451 |
Stock options | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Effect of dilutive securities (in shares) | 1,086,474 | 1,479,713 | 1,129,985 | 1,513,886 |
Restricted stock units | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Effect of dilutive securities (in shares) | 121,248 | 161,621 | 212,971 | 217,200 |
Net Income Per Share - Potentia
Net Income Per Share - Potential Common Share Equivalents Excluded from Computation of Diluted Net Income per Share (Details) - shares | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
Antidilutive securities excluded from computation of earnings per share (in shares) | 8,213,284 | 10,838,065 | 8,256,475 | 10,883,448 | |
1.25% Convertible Senior Notes | |||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
Antidilutive securities excluded from computation of earnings per share (in shares) | 0 | 5,910,954 | 0 | 5,910,954 | |
1.375% Convertible Senior Notes | |||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
Antidilutive securities excluded from computation of earnings per share (in shares) | 4,319,429 | 4,319,429 | 4,319,429 | 4,319,429 | |
0.375% Convertible Senior Notes | |||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
Antidilutive securities excluded from computation of earnings per share (in shares) | 3,528,400 | 0 | 3,528,400 | 0 | |
Unvested restricted stock units | |||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
Antidilutive securities excluded from computation of earnings per share (in shares) | 298,600 | 426,550 | 356,577 | 421,776 | |
Stock options | |||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
Antidilutive securities excluded from computation of earnings per share (in shares) | 66,855 | 181,132 | 52,069 | 231,289 | |
1.25% Convertible Senior Notes | |||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
Debt, interest rate | 1.25% | 1.25% | 1.25% | 1.25% | |
1.375% Convertible Senior Notes | |||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
Debt, interest rate | 1.375% | 1.375% | 1.375% | 1.375% | 1.375% |
0.375% Convertible Senior Notes | |||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||
Debt, interest rate | 0.375% | 0.375% | 0.375% | 0.375% | 0.375% |